Roche, Bio-Techne extend collaboration over mRNA ISH tissue analysis
Category: #health  By Mateen Dalal  Date: 2019-05-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Roche, Bio-Techne extend collaboration over mRNA ISH tissue analysis

Roche’s new detection kits have more translucent dyes which are suited for mRNA ISH co-localization studies

Swiss healthcare company Roche has recently announced that it has expanded its collaboration with Bio-Techne by providing drug discovery researchers in the U.S. with novel chromogenic detection kits for ISH (in situ hybridization) tissue analysis.

Apparently, the novel Roche kits are comprised of the DISCOVERY mRNA Purple HRP and Teal HRP detection kits. Both the teal and purple detection kits have more translucent dyes which are suited for mRNA ISH co-localization studies and feature the ability to perform ISH and immunohistochemistry (IHC) for co-detecting protein-RNA on same slides.

Citing reliable sources, designs of both these kits are aimed for using on Roche’s staining platform DISCOVERY ULTRA along with the enhanced signal-to-noise ratio and robustness of its newly released ACD RNAscope VS Universal HRP Reagent Kit.

Sources informed that mRNA Duplex AMP kit from Roche now has an extended application that allows dual mRNA ISH detection by using the latest mRNA Teal detection kit with the already available mRNA RED detection kit.

The red & teal combination offers a different visual contrast and the teal dye’s translucency enables the studying of mRNA ISH marks co-expressions, where the subsequent red and teal dyes overlap to create an indigo color. This new application is proposed for use with the newly launched RNAscope VS Duplex Reagent Kit that allows real-time in situ detection of two mRNA species.

Seemingly, the dual mRNA ISH application and new detection kits allow researchers to raise their multiplexing possibilities, while optimizing staining conditions for challenging probes and antibodies, conserving tissue samples, saving time and easily running complex assays.

Automating IHC and ISH on the DISCOVERY ULTRA platform allows scientists to create reproducible, standardized results and remove more than 90% of manual processes so that they can devote more time focusing on their research part, sources commented.

Source Credit: https://www.biospace.com/article/releases/roche-expands-partnership-with-bio-techne-to-offer-drug-discovery-researchers-new-chromogenic-detection-options-for-mrna-ish-tissue-analysis/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
By Mateen Dalal

Ambrx will receive additional development payments with Bristol-Meyers’ initiation of the Phase 1 clinical trial for Relaxin Ambrx Inc., a biopharmaceutical company focused on developing protein therapeutics, has recently announced that Bristo...

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
By Mateen Dalal

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acqu...

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...